Ming-Ming Shao

Dr. Ming-Ming Shao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in International Journal of Biological Sciences
Verified
Journal Article
Open access
PDF file
FYFeng-Shuang Yi
Feng-Shuang Yi
XQXin Qiao
Xin Qiao
SDShu-Feng Dong
Shu-Feng Dong
QCQing-Yu Chen
Qing-Yu Chen
RWRui-Qi Wei
Rui-Qi Wei
HSHuan-Zhong Shi
Huan-Zhong Shi
Macrophages play a crucial role in malignant pleural effusion (MPE), a frequent complication of advanced cancer. While C1q+ macrophages have been identified as a pro-tumoral cluster, direct evidence supporting the role of C1q-mediated macrophages remains to be elucidated. This study employed global and macrophage-specific knockout mice to investigate the role of C1q in MPE. The data demonstrated that C1q deficiency in macrophages suppressed MPE and prolonged mouse survival. scRNA-seq analysis of the C1qa-/- mouse MPE model revealed that C1q deficiency significantly decreased the proportion of M2 macrophages in MPE. In vitro experiments suggested that C1q expression was gradually upregulated during M2 polarization, which was C1q-dependent, as was antigen presentation. Deficiency of C1q in macrophages rescued the exhausted status of CD8+ T cells and enhanced the immune activity of CD8+ T cells and NK cells in both MPE and pleural tumors. Cell-to-cell interaction analysis demonstrated that C1q deficiency attenuated the immunoinhibitory effects of macrophages on NK cells by downregulating the CCR2-CCL2 signaling axis. Metabolomic analysis revealed significantly elevated hippuric acid levels in C1q-deficient mouse MPE. Treatment with either hippuric acid or a CCR2 antagonist inhibited MPE and tumor growth, with an even more pronounced effect observed when both treatments were combined.

8 March 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
MSMing-Ming Shao
Ming-Ming Shao
MSMeier Shi
Meier Shi
JDJuan Du
Juan Du
XPXue-Bin Pei
Xue-Bin Pei
BGBei-Bei Gu
Bei-Bei Gu
FYFeng-Shuang Yi
Feng-Shuang Yi
Abnormal function of immune cells is one of the key mechanisms leading to severe clinical symptoms in coronavirus disease 2019 patients, and metabolic pathways can destroy the function of the immune system by affecting innate and adaptive immune responses. However, the metabolic characteristics of the immune cells of the SARS-CoV-2 infected organs in situ remaining elusive. We reanalyzed the metabolic-related gene profiles in single-cell RNA sequencing data, drew the metabolic landscape in bronchoalveolar lavage fluid immune cells, and elucidated the metabolic remodeling mechanism that might lead to the progression of COVID-19 and the cytokine storm. Enhanced glycolysis is the most important common metabolic feature of all immune cells in COVID-19 patients. CCL2+ T cells, Group 2 macrophages with high SPP1 expression and myeloid dendritic cells are among the main contributors to the cytokine storm produced by infected lung tissue. Two metabolic analysis methods, including Compass, showed that glycolysis, fatty acid metabolism, bile acid synthesis and purine and pyrimidine metabolism levels of CCL2+ T cells, Group 2 macrophages and myeloid dendritic cells were upregulated and correlated with cytokine storms of COVID-19 patients. This might be the key metabolic regulatory factor for immune cells to produce large quantities of cytokines.

6 July 2023 in Frontiers in Microbiology
Verified
Journal Article
Open access
SZSheng-Cai Zheng
Sheng-Cai Zheng
ZHZhong-Yin Huang
Zhong-Yin Huang
KZKan Zhai
Kan Zhai
HSHuan-Zhong Shi
Huan-Zhong Shi
MSMing-Ming Shao
Ming-Ming Shao
Background: The simple, rapid, and accurate diagnosis of tuberculous pleural effusion (TPE) remains difficult. This study aimed to determine the accuracy of hepatocyte growth factor (HGF) in the diagnosis of TPE.Methods: We quantified the expression of HGF, adenosine deaminase (ADA), and interferon gamma (IFN-γ) in pleural effusion (PE) in 97 TPE subjects and 116 non-TPE subjects using an enzyme-linked immunosorbent assay (ELISA) or a fully automatic biochemical analyzer. The diagnostic performance of these three biomarkers was evaluated using a receiver operating characteristic (ROC) curve of subjects by age and gender.Results: We discovered that the TPE group had much higher levels of HGF than the non-TPE group, regardless of age or gender, and that there was no statistically significant difference between the two groups’ levels of HGF expression in peripheral plasma. In female TPE patients aged ≤65 years, the AUCs of TPE and non-TPE diagnosed by HGF, ADA or IFN-γ were 0.988, 0.964, and 0.827, respectively. HGF plus ADA had the highest diagnostic efficacy in female TPE patients aged ≤65 years. With HGF plus ADA having a cut-off value of 0.219 for distinguishing TPE from non-TPE, the area under the curve (AUC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), and negative predictive value (NPV) were, respectively, 0.998 (95% confidence interval [CI], 0.993–1.000), 100 (95% CI, 89.997–100.000), 96.667 (95% CI, 82.783–99.916), 97.222 (95% CI, 83.594–99.586), and 100.Conclusion: This study confirmed that HGF plus ADA has high diagnostic efficacy in younger female TPE patients and has the potential to be an excellent biomarker.

8 May 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
MSMing-Ming Shao
Ming-Ming Shao
LXLi Xin
Li Xin
RWRui-Qi Wei
Rui-Qi Wei
QCQing-Yu Chen
Qing-Yu Chen
XZXin Zhang
Xin Zhang
HLHui Li
Hui Li
Lung adenocarcinoma (LUAD) is the most prevalent histological type of lung cancer. Previous studies have reported that specific long noncoding RNAs (lncRNA) are involved in cancer development and progression. The phenotype and mechanism of ENST00000440028, named MSL3P1, an lncRNA referred to as a cancer-testis gene with potential roles in tumorigenesis and progression, have not been reported. MSL3P1 is overexpressed in LUAD tumor tissues, which is significantly associated with clinical characteristics, metastasis, and poor clinical prognosis. MSL3P1 promotes the metastasis of LUAD in vitro and in vivo. The enhancer reprogramming in LUAD tumor tissue is the major driver of the aberrant expression of MSL3P1. Mechanistically, owing to the competitive binding to CUL3 mRNA with ZFC3H1 protein (a protein involved in targeting polyadenylated RNA to exosomes and promoting the degradation of target mRNA), MSL3P1 can prevent the ZFC3H1-mediated RNA degradation of CUL3 mRNA and transport it to the cytoplasm. This activates the downstream epithelial-to-mesenchymal transition signaling pathway and promotes tumor invasion and metastasis. Implications: This study indicates that lncRNA MSL3P1 regulates CUL3 mRNA stability and promotes metastasis and holds potential as a prognostic biomarker and therapeutic target in LUAD.

17 June 2026
Verified
Other
Open access
MSMing-Ming Shao
Ming-Ming Shao
LXLi Xin
Li Xin
RWRui-Qi Wei
Rui-Qi Wei
QCQing-Yu Chen
Qing-Yu Chen
XZXin Zhang
Xin Zhang
HLHui Li
Hui Li
Lung adenocarcinoma (LUAD) is the most prevalent histological type of lung cancer. Previous studies have reported that specific long noncoding RNAs (lncRNA) are involved in cancer development and progression. The phenotype and mechanism of ENST00000440028, named MSL3P1, an lncRNA referred to as a cancer-testis gene with potential roles in tumorigenesis and progression, have not been reported. MSL3P1 is overexpressed in LUAD tumor tissues, which is significantly associated with clinical characteristics, metastasis, and poor clinical prognosis. MSL3P1 promotes the metastasis of LUAD in vitro and in vivo. The enhancer reprogramming in LUAD tumor tissue is the major driver of the aberrant expression of MSL3P1. Mechanistically, owing to the competitive binding to CUL3 mRNA with ZFC3H1 protein (a protein involved in targeting polyadenylated RNA to exosomes and promoting the degradation of target mRNA), MSL3P1 can prevent the ZFC3H1-mediated RNA degradation of CUL3 mRNA and transport it to the cytoplasm. This activates the downstream epithelial-to-mesenchymal transition signaling pathway and promotes tumor invasion and metastasis.Implications:This study indicates that lncRNA MSL3P1 regulates CUL3 mRNA stability and promotes metastasis and holds potential as a prognostic biomarker and therapeutic target in LUAD.

8 August 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
MSMing-Ming Shao
Ming-Ming Shao
SDShu-Feng Dong
Shu-Feng Dong
QCQing-Yu Chen
Qing-Yu Chen
RWRui-Qi Wei
Rui-Qi Wei
FYFeng-Shuang Yi
Feng-Shuang Yi
Diabetes is a prevalent endocrine disease frequently linked to obesity and associated with an increased cancer risk and mortality. Malignant pleural effusion (MPE), a common metastatic manifestation of advanced cancer, poses significant challenges in clinical management. This study aimed to investigate the potential impact of glucagon-like peptide-1 receptor agonists (GLP-1RA), a novel type of therapeutic agents for diabetes, on the progression and metabolomic profile of MPE in an obese mouse model. A high-fat diet was used to induce obesity in mice, while normal diet-fed mice served as controls. Once obesity was established, a model of MPE was further established by intrapleural injection of mouse Lewis lung carcinoma cells. In a subsequent treatment experiment, the mice either received daily GLP-1RA injections at a dosage of 100 µg/kg or normal saline as a control treatment, from the establishment of the MPE model until the end of the experiment. Two weeks later, pleural liquid samples were collected and subsequently subjected to metabolomic profiling using liquid chromatography-tandem mass/mass spectrometry. Pleural liquid volume was significantly elevated in obese mice with MPE. GLP-1RA effectively reduced blood glucose levels, suppressed MPE progression, and extended survival time in these mice. Metabolomics analysis revealed that amino acid metabolism was suppressed in the MPE of obese mice, whereas GLP-1RA significantly enhanced nucleic acid metabolism, particularly purine metabolism, in the MPE of these mice. Notably, minimal influence on metabolic pathways within MPE was observed when treating normal-weight mice with GLP-1RA. The findings offer a deeper understanding of the metabolic characteristics of MPE in obese mice and clarify the metabolic mechanism underlying the inhibitory effect of GLP-1RA on MPE progression in this population. These insights may provide theoretical support for designing innovative approaches in the treatment of cancer patients with obesity or diabetes. The online version contains supplementary material available at 10.1186/s12967-025-06875-8.